PLoS ONE (Jan 2021)

Detecting SARS-CoV-2 variants with SNP genotyping.

  • Helen Harper,
  • Amanda Burridge,
  • Mark Winfield,
  • Adam Finn,
  • Andrew Davidson,
  • David Matthews,
  • Stephanie Hutchings,
  • Barry Vipond,
  • Nisha Jain,
  • COVID-19 Genomics UK (COG-UK) Consortium,
  • Keith Edwards,
  • Gary Barker

DOI
https://doi.org/10.1371/journal.pone.0243185
Journal volume & issue
Vol. 16, no. 2
p. e0243185

Abstract

Read online

Tracking genetic variations from positive SARS-CoV-2 samples yields crucial information about the number of variants circulating in an outbreak and the possible lines of transmission but sequencing every positive SARS-CoV-2 sample would be prohibitively costly for population-scale test and trace operations. Genotyping is a rapid, high-throughput and low-cost alternative for screening positive SARS-CoV-2 samples in many settings. We have designed a SNP identification pipeline to identify genetic variation using sequenced SARS-CoV-2 samples. Our pipeline identifies a minimal marker panel that can define distinct genotypes. To evaluate the system, we developed a genotyping panel to detect variants-identified from SARS-CoV-2 sequences surveyed between March and May 2020 and tested this on 50 stored qRT-PCR positive SARS-CoV-2 clinical samples that had been collected across the South West of the UK in April 2020. The 50 samples split into 15 distinct genotypes and there was a 61.9% probability that any two randomly chosen samples from our set of 50 would have a distinct genotype. In a high throughput laboratory, qRT-PCR positive samples pooled into 384-well plates could be screened with a marker panel at a cost of < £1.50 per sample. Our results demonstrate the usefulness of a SNP genotyping panel to provide a rapid, cost-effective, and reliable way to monitor SARS-CoV-2 variants circulating in an outbreak. Our analysis pipeline is publicly available and will allow for marker panels to be updated periodically as viral genotypes arise or disappear from circulation.